
ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review
Description
ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
ICON Plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. The company provides specialized services that span the entire lifecycle of product development. ICON’s service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, provision of functional services, medical imaging, resourcing solutions, laboratory services and strategic support and tactical solutions for traditional, in vitro diagnostic and software devices. The company offers research services in areas of cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, non-alcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines, and women’s health, among others. ICON is headquartered in Dublin, Ireland.
ICON Plc Key Recent Developments
Jul 23,2025: ICON Reports Second Quarter 2025 Results
Jul 16,2025: ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
Jun 23,2025: ICON Schedules Second Quarter 2025 Earnings Conference Call
May 07,2025: Global Icon Survey Shows Need for More Efficient Obesity Clinical Trial Design to Realise Full Potential of Next-Gen Multi-Indication Therapies
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
ICON Plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. The company provides specialized services that span the entire lifecycle of product development. ICON’s service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, provision of functional services, medical imaging, resourcing solutions, laboratory services and strategic support and tactical solutions for traditional, in vitro diagnostic and software devices. The company offers research services in areas of cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, non-alcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines, and women’s health, among others. ICON is headquartered in Dublin, Ireland.
ICON Plc Key Recent Developments
Jul 23,2025: ICON Reports Second Quarter 2025 Results
Jul 16,2025: ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
Jun 23,2025: ICON Schedules Second Quarter 2025 Earnings Conference Call
May 07,2025: Global Icon Survey Shows Need for More Efficient Obesity Clinical Trial Design to Realise Full Potential of Next-Gen Multi-Indication Therapies
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
64 Pages
- Section 1 - About the Company
- ICON Plc - Key Facts
- ICON Plc - Key Employees
- ICON Plc - Key Employee Biographies
- ICON Plc - Major Products and Services
- ICON Plc - History
- ICON Plc - Company Statement
- ICON Plc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- ICON Plc - Business Description
- Geographical Segment: Ireland
- Performance
- Geographical Segment: Other
- Performance
- Geographical Segment: Rest of Europe
- Performance
- Geographical Segment: U.S.
- Performance
- R&D Overview
- ICON Plc - Corporate Strategy
- ICON Plc - SWOT Analysis
- SWOT Analysis - Overview
- ICON Plc - Strengths
- ICON Plc - Weaknesses
- ICON Plc - Opportunities
- ICON Plc - Threats
- ICON Plc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences, Oil & Gas Financial Deals and Alliances
- ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- ICON Plc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- ICON Plc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Jul 23, 2025: ICON Reports Second Quarter 2025 Results
- Jul 16, 2025: ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
- Jun 23, 2025: ICON Schedules Second Quarter 2025 Earnings Conference Call
- May 07, 2025: Global Icon Survey Shows Need for More Efficient Obesity Clinical Trial Design to Realise Full Potential of Next-Gen Multi-Indication Therapies
- Feb 19, 2025: ICON reports fourth quarter and full year 2024 results
- Jan 30, 2025: Icon Portfolio of AI Tools Drives Clinical Trial Efficiencies
- Dec 18, 2024: ICON announces Appointment of Chief Operating Officer
- Sep 03, 2024: ICON to Present at the Baird 2024 Global Healthcare Conference
- Aug 14, 2024: ICON Announces Appointment of New Chief Financial Officer
- Jul 24, 2024: ICON Announces Results of Annual General Meeting and Changes to the Board of Directors
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- ICON Plc, Key Facts
- ICON Plc, Key Employees
- ICON Plc, Key Employee Biographies
- ICON Plc, Major Products and Services
- ICON Plc, History
- ICON Plc, Subsidiaries
- ICON Plc, Key Competitors
- ICON Plc, Ratios based on current share price
- ICON Plc, Annual Ratios
- ICON Plc, Annual Ratios (Cont...1)
- ICON Plc, Annual Ratios (Cont...2)
- ICON Plc, Interim Ratios
- ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- ICON Plc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- ICON Plc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- ICON Plc, Performance Chart (2020 - 2024)
- ICON Plc, Ratio Charts
- ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- ICON Plc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.